The link between the hemostasis system and schizophrenia patients clinical status: an experience of the Fibrinodynamics method administration

Background. A multiple and variable interrelations between the blood coagulation disorders, neuroinflammation and the psychotic syndromes pathogenesis mean an obvious scientific and clinical validity of the hemostasis system research in schizophrenia. This interdisciplinary track deals with a link between psychiatry, neurobiology and hematology. This itself is a step towards the new perspectives for further understanding of schizophrenia pathophysiology, and, consequently, for developments of the forth-coming therapeutic approaches.

The aim. Evaluation of the role of the hemostasis system using the “Fibrinodynamics” method in the pathophysiology of schizophrenia.

Materials and Methods. An observational cohort study was conducted on 66 female patients aged 16–57 years (32.2 ± 10.2 years) hospitalized in the clinic of the Mental Health Research Center in the acute stage of the disease. Blood coagulation and fibrinolysis patterns were detected and analysed using our original version of “Fibrinodynamics” method, while the patients` clinical status was elucidated by PANSS and HDRS scales.

Results. Prior to treatment, a statistically significant increase of all “Fibrinodynamics” control values, except for a hemostasis balance parameter (OFP%, p = 0.337) has been observed. This shows a high potential of coagulation (OCP, p < 0.0001) and fibrinolysis (OFP, p < 0.0001), whereas the whole system balance was found intact.

After the treatment, a clear hemostasis disbalances (OFP%, p = 0.394) with a probable predominance of coagulation and/or fibrinolytic potential in different patients (OCP, p <0.0001; OFP, p <0.0001): a lack of statistically essential changes of these parameters was demonstrated within this group in general.

Conclusion. The data obtained are in a favor to a statistically significant increase of the hemostasis function parameters in schizophrenia patients which correlates with their clinical status. This indicates to involvement of the hemostasis system into pathopysiology of the disease studied.

Taking into account the link between inflammation and hemostasis we’ve found, these results allows to assume an essential interrelation between the hemostasis disfunction and chronic inflammation, as long as both takes place in schizophrenia patients. It seems to be an important element of the disease pathogenesis path.

1. Stahl SM. Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications 4th ed. Cambridge University Press, Cambridge, 2013.

2. Psychiatry. National Leadership. Geotar-Media publishing house, edited by Alexandrovsky Yu.A., Neznanov N.G., 2022.

3. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020; 19(1): 15-33. doi: 10.1002/wps.20693

4. Klyushnik TP, Zozulya SA. Immunology of Schizophrenia: A Modern View on Inflammatory Hypotheses of the Disease. Psychiatry. 2024; 22(4): 14–25. (In Russ.). doi: 10.30629/2618-6667-2024-22-4-14-25

5. Nayak U, Manikkath J, Arora D, Mudgal J. Impact of neuroinflammation on brain glutamate and dopamine signalling in schizophrenia: an update. Metab Brain Dis. 2025; 40(2): 119. doi: 10.1007/s11011-025-01548-3

6. Navarrete S, Solar C, Tapia R, Pereira J, Fuentes E, Palomo I. Pathophysiology of deep vein thrombosis. Clin Exp Med. 2023; 23(3): 645-654. doi: 10.1007/s10238-022-00829-w

7. SchrottmaierWC, Assinger A.The Concept ofThromboinflammation. Hamostaseologie. 2024; 44(1): 21-30. Doi: 10.1055/a-2178-6491

8. Klavina PA, Leon G, Curtis AM, Preston RJS. Dysregulated haemostasis in thrombo-inflammatory disease. Clin Sci (Lond). 2022; 136(24): 1809–1829. doi: 10.1042/CS20220208

9. Chanchal S, Mishra A, Singh MK, Ashraf MZ. Understanding Inflammatory Responses in the Manifestation of Prothrombotic Phenotypes. Front Cell Dev Biol. 2020; 8: 73. doi: 10.3389/fcell.2020.00073

10. Luo YuF, Dong WCh, Yuan LYi, Zhu AYuQ, Zhang DD, et al. The Role of Thrombo-inflammation in Ischemic Stroke: Focus on the Manipulation and Clinical Application. Mol Neurobiol. 2025; 62(2): 2362-2375. doi: 10.1007/s12035-024-04397-w

11. Chan JKN, Wong CSM, Yung NCL, Chen EYH, Chang WC. Excess mortality and life-years lost in people with bipolar disorder: an 11-year population-based cohort study. Epidemiology and Psychiatric Sciences. 2021; 30: e39. doi: 10.1017/S2045796021000305

12. Paljärvi T, Herttua K, Taipale H, Lähteenvuo M, Tanskanen A, Fazel S, et al. Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study. BMJ Ment Health. 2023; 26(1): e300700. doi: 10.1136/bmjment-2023-300700

13. Santa Cruz EC, Zandonadi FDS, Fontes W, Sussulini A. A pilot study indicating the dysregulation of the complement and coagulation cascades in treated schizophrenia and bipolar disorder patients. Biochim Biophys Acta Proteins Proteom. 2021; 1869(8): 140657. doi: 10.1016/j.bbapap.2021.140657

14. Nakada Sh, Ho FK, Celis-Morales C, Pell JP. Schizophrenia and Types of Stroke: A Mendelian Randomization Study. J Am Heart Assoc. 2024; 13(5): e032011. doi: 10.1161/JAHA.123.032011

15. Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. Nat Rev Cardiol. 2021; 18(2): 136-145. doi: 10.1038/s41569-020-00463-7

16. Castillo-Sánchez M, Escurriola MF, Fernández Sanmartín MI, Solntseva I, Baquero DB, et al. Cardiovascular disease and mortality in people with schizophrenia or antipsychotic treatment: A cohort study in primary care. Psychiatry Res. 2021; 306: 114233. doi: 10.1016/j.psychres.2021.114233

17. Hoirisch-Clapauch S, Nardi AE. Psychiatric remission with warfarin: should psychosis be addressed as plasminogen activator imbalance. Med Hypotheses. 2013; 80: 137–141. doi: 10.1016/j.mehy.2012.11.011

18. Ministry of Health of the Russian Federation. Clinical guidelines. URL: https://cr.minzdrav.gov.ru/preview-cr/451_3. [date of access: October 13, 2025].

19. Peralta V, Cuesta MJ. Psychometric properties of the positive and negative syndrome scale (PANSS) in schizophrenia. Psychiatry Res. 1994; 53(1): 31-40. doi: 10.1016/0165-1781(94)90093-0

20. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry. 1960; 23(1): 56–62. doi: 10.1136/jnnp.23.1.56

21. Hemacore. Innovative diagnostics of blood coagulation. URL: https://gemakor.ru/?ysclid=mgp-30g21r1891130735 [date of access: October 13, 2025].

22. Bernshtein JD, Brusov OS, Matveev IA. Methods for in vitro determination of coagulation and fibrinolysis characteristics using the blood plasma images sequence. 2015; 1(12): 39-48. (In Russ.).

23. Karpova NS, Brusov OS, Oleychik IV, Stolyarov SA, Klyushnik TP. The state of the hemostasis system in patients with schizophrenia and schizophrenic spectrum disorders. Bulletin of Experimental Biology and Medicine. 2023; 176(9): 375-379. (In Russ.). doi: 10.47056/0365-9615-2023-176-9-375-379

24. Lang TA, Sesik M. How to describe statistics in medicine. Moscow, Practical Medicine, 2011. (In Russ.).

25. Hasni D, Anggraini D, Anissa M. A Review of Antipsychotic Medications on Hypercoagulability in Schizophrenia: Pathophysiology, Risks, and Management Strategies. Journal of Angiotherapy. 2024; 8(12), 1-9: 10063. doi: 10.25163/angiotherapy.81210063

26. Hashimoto H, Imai Sh, Yamashita R, Kiyomi A, Sugiura M. Association of Antipsychotic Drugs with the Risk of Recurrent Venous Thromboembolism: A Retrospective Study of Data from a Japanese Inpatient Database. Drugs Real World Outcomes. 2024; 11(1): 109-116. doi: 10.1007/s40801-023-00401-2

27. Arasteh O, Nomani H, Baharara H, Sadjadi SA, Mohammadpour AH, Ghavami V, et al. Antipsychotic Drugs and Risk of Developing Venous Thromboembolism and Pulmonary Embolism: A Systematic Review and Meta-Analysis. Curr Vasc Pharmaco. 2020; 18(6): 632-643. doi: 10.2174/1570161118666200211114656

28. Hoirisch-Clapauch S, Amaral O, Mezzasalma M, et al. Dysfunction in the coagulation system and schizophrenia. Transl Psychiatry. 2016; 6: e704. doi: 10.1038/tp.2015.204

29. Chow V, Reddel C, Pennings G, Scott E, Pasqualon T, Ng AC, et al. Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy. Schizophr Res. 2015; 162(1-3): 175-82. doi: 10.1016/j.schres.2014.12.042

30. Zheng C, Liu H, Tu W, Lin L, Xu H. Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications. Ther Adv Psychopharmacol. 2023; 13: 20451253231200257. doi: 10.1177/20451253231200257

31. Hoirisch-Clapauch S, Amaral O, Mezzasalma M, et al. Dysfunction in the coagulation system and schizophrenia. Transl Psychiatry. 2016; 6: e704. doi: 10.1038/tp.2015.204

32. Grosu C, Klauser P, Dwir D, Khadimallah I, Alemán-Gómez Y, Laaboub N, et al. Associations between antipsychotics-induced weight gain and brain networks of impulsivity. Transl Psychiatry. 2024; 14(1): 162. doi: 10.1038/s41398-024-02881-4